Gain Therapeutics, Inc. (NASDAQ:GANX) Stock Has Average Target Price of $7.67 According to Brokerages

Gain Therapeutics, Inc. (NASDAQ:GANX) has been given a consensus recommendation of “Moderate Buy” by the five research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $7.67.

A number of analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Monday, October 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Friday, September 4th. Finally, BTIG Research reissued a “buy” rating and set a $5.00 price target on shares of Gain Therapeutics in a research report on Monday, October 5th.

Gain Therapeutics Price Performance

NASDAQ:GANX opened at $1.13 on Thursday. Gain Therapeutics has a one year low of $1.11 and a one year high of $4.34. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.36 and a current ratio of 4.36. The stock has a market cap of $49.31 million, a PE ratio of -2.26 and a beta of 0.19. The stock has a 50 day moving average price of $1.62 and a 200 day moving average price of $1.86.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. Equities research analysts expect that Gain Therapeutics will post -0.50 EPS for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

A number of institutional investors have recently bought and sold shares of the company. HB Wealth Management LLC purchased a new stake in shares of Gain Therapeutics in the 2nd quarter valued at approximately $26,000. Two Sigma Securities LLC purchased a new stake in shares of Gain Therapeutics during the 2nd quarter valued at approximately $26,000. BOKF NA purchased a new stake in shares of Gain Therapeutics during the 3rd quarter valued at approximately $35,000. HighTower Advisors LLC acquired a new position in Gain Therapeutics in the second quarter valued at approximately $35,000. Finally, Apollon Wealth Management LLC lifted its holdings in Gain Therapeutics by 33.7% in the first quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock valued at $51,000 after acquiring an additional 6,675 shares during the last quarter. 11.97% of the stock is owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms.

Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease.